Literature DB >> 28622620

Simultaneous UHPLC-UV analysis of hydroxychloroquine, minocycline and doxycycline from serum samples for the therapeutic drug monitoring of Q fever and Whipple's disease.

Nicholas Armstrong1, Magali Richez2, Didier Raoult2, Eric Chabriere2.   

Abstract

A fast UHPLC-UV method was developed for the simultaneous analysis of Hydroxychloroquine, Minocycline and Doxycycline drugs from 100μL of human serum samples. Serum samples were extracted by liquid-liquid extraction and injected into a phenyl hexyl reverse phase column. Compounds were separated using a mobile phase linear gradient and monitored by UV detection at 343nm. Chloroquine and Oxytetracycline were used as internal standards. Lower and upper limits of quantifications, as well as the other levels of calibration, were validated with acceptable accuracy (<15% deviation) and precision (<15% coefficient of variation) according to the European Medicines Agency guidelines. This new method enables cost and time reduction and was considered suitable for the clinical laboratory. It is the first published assay for the therapeutic drug monitoring of patients diagnosed with Q fever or Whipple's disease.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Doxycycline; Hydroxychloroquine; Minocycline; Q fever; UHPLC; UV; Whipple’s disease

Mesh:

Substances:

Year:  2017        PMID: 28622620     DOI: 10.1016/j.jchromb.2017.06.011

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  5 in total

Review 1.  Review of Chromatographic Methods Coupled with Modern Detection Techniques Applied in the Therapeutic Drugs Monitoring (TDM).

Authors:  Tomasz Tuzimski; Anna Petruczynik
Journal:  Molecules       Date:  2020-09-03       Impact factor: 4.411

2.  Development and Validation of a Simple and Rapid Ultrahigh-Performance Liquid Chromatography Tandem Spectrometry Method for the Quantification of Hydroxychloroquine in Plasma and Blood Samples in the Emergency Context of SARS-CoV-2 Pandemic.

Authors:  Natalia Doudka; Madeleine Giocanti; Manon Basso; Renée Ugdonne; Karine Barthelemy; Bruno Lacarelle; Olivier Blin; Caroline Solas; Romain Guilhaumou
Journal:  Ther Drug Monit       Date:  2021-08-01       Impact factor: 3.681

3.  Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France.

Authors:  Matthieu Million; Jean-Christophe Lagier; Philippe Gautret; Philippe Colson; Pierre-Edouard Fournier; Sophie Amrane; Marie Hocquart; Morgane Mailhe; Vera Esteves-Vieira; Barbara Doudier; Camille Aubry; Florian Correard; Audrey Giraud-Gatineau; Yanis Roussel; Cyril Berenger; Nadim Cassir; Piseth Seng; Christine Zandotti; Catherine Dhiver; Isabelle Ravaux; Christelle Tomei; Carole Eldin; Hervé Tissot-Dupont; Stéphane Honoré; Andreas Stein; Alexis Jacquier; Jean-Claude Deharo; Eric Chabrière; Anthony Levasseur; Florence Fenollar; Jean-Marc Rolain; Yolande Obadia; Philippe Brouqui; Michel Drancourt; Bernard La Scola; Philippe Parola; Didier Raoult
Journal:  Travel Med Infect Dis       Date:  2020-05-05       Impact factor: 6.211

4.  In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect.

Authors:  Julien Andreani; Marion Le Bideau; Isabelle Duflot; Priscilla Jardot; Clara Rolland; Manon Boxberger; Nathalie Wurtz; Jean-Marc Rolain; Philippe Colson; Bernard La Scola; Didier Raoult
Journal:  Microb Pathog       Date:  2020-04-25       Impact factor: 3.738

5.  Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.

Authors:  Philippe Gautret; Jean-Christophe Lagier; Philippe Parola; Van Thuan Hoang; Line Meddeb; Morgane Mailhe; Barbara Doudier; Johan Courjon; Valérie Giordanengo; Vera Esteves Vieira; Hervé Tissot Dupont; Stéphane Honoré; Philippe Colson; Eric Chabrière; Bernard La Scola; Jean-Marc Rolain; Philippe Brouqui; Didier Raoult
Journal:  Int J Antimicrob Agents       Date:  2020-03-20       Impact factor: 5.283

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.